Lung Diseases  >>  roflumilast  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
roflumilast / Generic mfg.
NCT01365533: A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma

Completed
2
48
Canada
Roflumilast, Placebo
AstraZeneca
Allergic Asthma
07/05
07/05
NCT01765192 / 2012-002064-27: Roflumilast Plus Montelukast in Adults With Severe Asthma

Completed
2
64
Europe, RoW
Roflumilast, Daxas, Daliresp, Roflumilast placebo, Montelukast, Singulair, Pluralair
AstraZeneca
Asthma
10/13
10/13
NCT01473758 / 2011-002905-31: Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Terminated
2
81
Europe
Roflumilast, Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
03/14
03/14
RAMBO, NCT01701934: Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease

Terminated
2
14
Canada
Roflumilast, DAXAS, Placebo, Inactive comparator
Laval University, Innovair, Takeda
Chronic Obstructive Pulmonary Disease, Metabolic Syndrome
10/14
12/14

Download Options